All In Biotech

Drug Trial Radar · NCT07052903

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

TRITON-CM: A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Transthyretin-Mediated Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 2,250 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

2,250

Planned (sponsor's estimate)

Start

Jul 2, 2025

Primary completion

May 28, 2030

Study completion Nov 30, 2032

Sponsor

Lead sponsor
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
Sponsor type
Industry
First posted
Jul 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to: * Evaluate the efficacy of nucresiran compared to placebo on reducing all-cause mortality and cardiovascular (CV) events * Evaluate the efficacy of nucresiran compared to placebo on additional assessments of CV events and/or death * Evaluate the efficacy of nucresiran compared to placebo on patient-reported health status and health-related quality of life

Conditions

  • Transthyretin Amyloidosis With Cardiomyopathy

Interventions

  • NucresiranDrug

    Nucresiran 300 mg administered SC q6M

  • Sterile Normal Saline (0.9% NaCl)Drug

    Sterile Normal Saline (0.9% NaCl) administered SC once q6M

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite outcome of all-cause mortality and recurrent cardiovascular [CV] events (CV hospitalizations and urgent heart failure [HF] visits)Time frame: Baseline to end of double-blind period (estimated 32 months, maximum 5 years)

Locations

267 sites in 36 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    La Jolla, California · Recruiting

  • Clinical Trial Site

    Laguna Hills, California · Recruiting

  • Clinical Trial Site

    Stanford, California · Recruiting

  • Clinical Trial Site

    Aurora, Colorado · Recruiting

  • Clinical Trial Site

    Norwich, Connecticut · Recruiting

  • Clinical Trial Site

    Washington D.C., District of Columbia · Recruiting

  • Clinical Trial Site

    Brandon, Florida · Recruiting

  • Clinical Trial Site

    Miami, Florida · Recruiting

  • Clinical Trial Site

    Atlanta, Georgia · Recruiting

  • Clinical Trial Site

    Gainesville, Georgia · Recruiting

  • Clinical Trial Site

    Tucker, Georgia · Recruiting

  • Clinical Trial Site

    Chicago, Illinois · Recruiting

  • Clinical Trial Site

    Evanston, Illinois · Recruiting

  • Clinical Trial Site

    Indianapolis, Indiana · Recruiting

  • Clinical Trial Site

    Indianapolis, Indiana · Recruiting

  • Clinical Trial Site

    Kansas City, Kansas · Recruiting

  • Clinical Trial Site

    Baltimore, Maryland · Recruiting

  • Clinical Trial Site

    Boston, Massachusetts · Recruiting

  • Clinical Trial Site

    Boston, Massachusetts · Recruiting

  • Clinical Trial Site

    Detroit, Michigan · Recruiting

  • Clinical Trial Site

    Rochester, Minnesota · Recruiting

  • Clinical Trial Site

    St Louis, Missouri · Recruiting

  • Clinical Trial Site

    Manhasset, New York · Recruiting

  • Clinical Trial Site

    New York, New York · Recruiting

  • Clinical Trial Site

    New York, New York · Recruiting

  • Clinical Trial Site

    New York, New York · Recruiting

  • Clinical Trial Site

    The Bronx, New York · Recruiting

  • Clinical Trial Site

    Charlotte, North Carolina · Recruiting

  • Clinical Trial Site

    Cleveland, Ohio · Recruiting

  • Clinical Trial Site

    Columbus, Ohio · Recruiting

  • Clinical Trial Site

    Portland, Oregon · Recruiting

  • Clinical Trial Site

    Lancaster, Pennsylvania · Recruiting

  • Clinical Trial Site

    Philadelphia, Pennsylvania · Recruiting

  • Clinical Trial Site

    Charleston, South Carolina · Recruiting

  • Clinical Trial Site

    Austin, Texas · Recruiting

  • Clinical Trial Site

    Dallas, Texas · Recruiting

  • Clinical Trial Site

    Houston, Texas · Recruiting

  • Clinical Trial Site

    Plano, Texas · Recruiting

  • Clinical Trial Site

    Salt Lake City, Utah · Recruiting

  • Clinical Trial Site

    Charlottesville, Virginia · Recruiting

Showing 40 of 267 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.